Literature DB >> 21385239

Disability and cost for diabetic patients at a public district hospital in Thailand.

Arthorn Riewpaiboon1, Susmita Chatterjee, Wachara Riewpaiboon, Piyanuch Piyauthakit.   

Abstract

OBJECTIVE: The study determined the rate of disability among diabetic patients at a public district hospital in Thailand and compared the costs of illness among different levels of severity of disability. This was the first such study carried out in Thailand.
METHODS: The study was conducted at Waritchaphum Hospital in northeastern Thailand. Data were collected from 475 randomly selected diabetic patients identified by the World Health Organization's International Classification of Diseases, tenth revision (ICD-10 codes E10 - E14) who received treatment from the study hospital during the fiscal year of 2008. The disability levels were determined by using Thailand ministerial guidelines as well as the Barthel index score. Cost-of-illness estimates followed the prevalence-based approach and it presented the societal perspective of cost-of-illness of diabetes in 2008. KEY
FINDINGS: The study results showed that 9.68% of the study participants had physical impairment while 9.26% had impairment in eyesight. The Barthel index score showed that 13.5% of the study participants were disabled. When comparing costs between independent and disabled persons, considering the Barthel index score, average costs for the disabled diabetic persons were significantly higher than for those who were independent (US$2700.29 versus 598.24; P<0.001).
CONCLUSIONS: The study concluded that the presence of complications and disability among diabetic patients impacts severely on Thai society. At present, the Thai government allocates US$187.5 per annum to registered disabled persons as a disability living allowance. The study found a large difference between the direct economic outlay of the patients and the allowance provided, which suggests that there is probably a need to revise the welfare payment upwards.
© 2011 The Authors. IJPP © 2011 Royal Pharmaceutical Society.

Entities:  

Mesh:

Year:  2011        PMID: 21385239     DOI: 10.1111/j.2042-7174.2010.00078.x

Source DB:  PubMed          Journal:  Int J Pharm Pract        ISSN: 0961-7671


  4 in total

Review 1.  Diabetes in Thailand: Status and Policy.

Authors:  Sirimon Reutrakul; Chaicharn Deerochanawong
Journal:  Curr Diab Rep       Date:  2016-03       Impact factor: 4.810

2.  Economic Burdens for Treatment of Patients With Type 2 Diabetes in North Thailand: A Hospital-Based Observational Study.

Authors:  Arintaya Phrommintikul; Piyameth Dilokthornsakul; Unchalee Permsuwan
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-16       Impact factor: 6.055

3.  Cost-Utility Analysis of Dapagliflozin as an Add-On to Standard Treatment for Patients with Type 2 Diabetes and High Risk of Cardiovascular Disease in Thailand.

Authors:  Chaicharn Deerochanawong; Kriengsak Vareesangthip; Dilok Piyayotai; Dittaya Thongsuk; Nuch Pojchaijongdee; Unchalee Permsuwan
Journal:  Diabetes Ther       Date:  2021-06-09       Impact factor: 2.945

Review 4.  Diabetes management in Thailand: a literature review of the burden, costs, and outcomes.

Authors:  Chaicharn Deerochanawong; Alessandra Ferrario
Journal:  Global Health       Date:  2013-03-14       Impact factor: 4.185

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.